ERBB2 and breast carcinoma: In an interim analysis of the phase Ib trial of T-DXd with nivolumab in patients with advanced/metastatic HER2-positive or HER2-low-expressing breast cancer (NCT03523572; DS8201-A-U105; N = 48), the types and rates of reported AEs were consistent with those seen with T-DXd monotherapy.71